1. Introduction to Antibiotics in Modern Medicine
Antibiotics — more precisely termed antibacterials — are among the most consequential pharmaceutical discoveries in medical history. Since the serendipitous identification of penicillin by Alexander Fleming in 1928 and its clinical development by Florey and Chain in the 1940s, antibiotic pharmacology has expanded to encompass dozens of structural classes, thousands of individual agents, and an increasingly complex landscape of antimicrobial resistance that constitutes one of the most pressing global public health challenges of the 21st century.
In Canada, antibiotics are among the most commonly prescribed medications. The Public Health Agency of Canada (PHAC) estimates that approximately 26 million antibiotic prescriptions are dispensed annually in the Canadian community setting alone. Of particular concern is that conservative estimates suggest 30–50% of antibiotic prescriptions in both Canadian and US outpatient settings are either unnecessary (viral infections that do not respond to antibiotics) or prescribed with suboptimal agent selection, dose, or duration.
This academic guide provides an overview of antibiotic mechanisms of action, major drug classes with representative agents, clinically relevant resistance mechanisms, and the framework of antimicrobial stewardship as implemented in the Canadian healthcare context under Health Canada oversight and Public Health Agency of Canada guidelines.
2. Mechanisms of Antibacterial Action
Antibiotics exert their bactericidal or bacteriostatic effects through several distinct molecular mechanisms, each targeting a structure or process essential to bacterial survival that is either absent in or sufficiently different from human cells to provide therapeutic selectivity.
Cell Wall Synthesis Inhibition
Penicillins, cephalosporins, carbapenems, and monobactams inhibit penicillin-binding proteins (PBPs), preventing peptidoglycan cross-linking in the bacterial cell wall. Glycopeptides (vancomycin) bind D-Ala-D-Ala termini of peptidoglycan precursors. Without an intact cell wall, bacteria lyse via osmotic pressure.
Protein Synthesis Inhibition
Aminoglycosides and tetracyclines target the 30S ribosomal subunit; macrolides, lincosamides, streptogramins, and chloramphenicol target the 50S subunit. Oxazolidinones (linezolid) prevent 70S ribosome assembly. These mechanisms exploit structural differences between prokaryotic (70S) and eukaryotic (80S) ribosomes.
Nucleic Acid Synthesis Inhibition
Fluoroquinolones inhibit bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication and repair. Rifamycins (rifampin) inhibit bacterial DNA-dependent RNA polymerase, blocking transcription. Metronidazole generates reactive nitroso intermediates that damage DNA in anaerobic organisms.
Cell Membrane Disruption
Polymyxins (colistin, polymyxin B) disrupt Gram-negative bacterial outer membrane integrity by binding lipopolysaccharide (LPS). Daptomycin inserts into the cytoplasmic membrane of Gram-positive bacteria, causing rapid membrane depolarization and cell death. These represent last-resort agents for resistant infections.
Metabolic Pathway Inhibition
Sulfonamides competitively inhibit dihydropteroate synthase, blocking folate synthesis from para-aminobenzoic acid (PABA). Trimethoprim inhibits dihydrofolate reductase (DHFR), preventing conversion of dihydrofolate to tetrahydrofolate. Their combination (co-trimoxazole, TMP-SMX) produces sequential blockade of the folate pathway with synergistic bactericidal activity.
3. Major Antibiotic Drug Classes
The following table summarizes the major antibiotic classes approved under Health Canada, their primary mechanism, representative agents, spectrum of activity, and common clinical applications in Canadian practice.
| Class | Mechanism | Key Agents | Spectrum | Common Indications (Canada) |
|---|---|---|---|---|
| Penicillins | PBP inhibition (cell wall) | Amoxicillin, Ampicillin, Cloxacillin | Gram+, some Gram− | Otitis media, sinusitis, strep pharyngitis |
| Cephalosporins | PBP inhibition (cell wall) | Cephalexin (1st), Cefuroxime (2nd), Ceftriaxone (3rd) | Broad (gen. dependent) | UTI, pneumonia, skin infections, meningitis |
| Carbapenems | PBP inhibition (broad) | Meropenem, Imipenem, Ertapenem | Very broad | Hospital-acquired infections, ESBL-producing organisms |
| Macrolides | 50S ribosome inhibition | Azithromycin, Clarithromycin, Erythromycin | Gram+, atypicals | Community pneumonia, atypical pathogens, H. pylori |
| Fluoroquinolones | Topoisomerase inhibition | Ciprofloxacin, Levofloxacin, Moxifloxacin | Broad, incl. Gram− | Complicated UTI, respiratory infections, traveler's diarrhea |
| Tetracyclines | 30S ribosome inhibition | Doxycycline, Minocycline, Tetracycline | Broad, incl. atypicals | Lyme disease, acne, chlamydia, MRSA (doxy) |
| Aminoglycosides | 30S ribosome inhibition | Gentamicin, Tobramycin, Amikacin | Gram−, Mycobacteria | Serious Gram-negative infections (hospital); synergy in endocarditis |
| Glycopeptides | Cell wall precursor binding | Vancomycin, Teicoplanin | Gram+ only (incl. MRSA) | MRSA infections, C. difficile (oral vanco), PCN-allergic endocarditis |
| Sulfonamides/TMP | Folate pathway inhibition | TMP-SMX (Co-trimoxazole) | Broad | UTI, Pneumocystis pneumonia (PCP), MRSA (community) |
| Nitroimidazoles | DNA damage (anaerobes) | Metronidazole, Tinidazole | Anaerobes, protozoa | C. difficile, bacterial vaginosis, H. pylori, amebiasis |
4. Antimicrobial Resistance Mechanisms
Antimicrobial resistance (AMR) represents the capacity of bacteria to survive and proliferate in the presence of antibiotic concentrations that would otherwise inhibit or kill susceptible organisms. The WHO has classified AMR as one of the top global public health threats, and Canada's Pan-Canadian Action Plan on Antimicrobial Resistance and Use (2023) outlines a coordinated federal-provincial response.
Enzymatic Inactivation
The most clinically prevalent resistance mechanism. Beta-lactamases hydrolyze the beta-lactam ring of penicillins and cephalosporins, inactivating the drug. Extended-spectrum beta-lactamases (ESBLs), found commonly in E. coli and Klebsiella pneumoniae, confer resistance to most penicillins and cephalosporins. Carbapenemases (KPC, NDM, OXA-48) threaten even last-resort carbapenem agents. Aminoglycoside-modifying enzymes (acetyltransferases, phosphotransferases, nucleotidyltransferases) similarly inactivate aminoglycosides.
Target Site Modification
Mutation or enzymatic modification of the antibiotic's molecular target reduces drug-target affinity. MRSA acquires the mecA gene encoding PBP2a — a modified penicillin-binding protein with low affinity for all beta-lactams. Fluoroquinolone resistance arises from mutations in gyrA (DNA gyrase) and parC (topoisomerase IV). Rifampin resistance results from rpoB mutations in the RNA polymerase beta subunit.
Efflux Pump Overexpression
Bacteria express membrane-embedded efflux pump systems that actively transport antibiotics out of the cell before intracellular concentrations reach inhibitory levels. The MexAB-OprM and related RND-family efflux systems in Pseudomonas aeruginosa confer intrinsic resistance to multiple antibiotic classes simultaneously, representing a major challenge in hospital-acquired Pseudomonas infections.
Permeability Reduction / Porin Loss
Gram-negative bacteria can downregulate or structurally modify outer membrane porins (OmpC, OmpF), reducing antibiotic entry into the periplasmic space. Combined with efflux overexpression, porin loss creates high-level resistance to carbapenems and other agents. This mechanism is particularly relevant in carbapenem-resistant Enterobacterales (CRE).
5. Antimicrobial Stewardship: Principles and Practice
Antimicrobial stewardship programs (ASPs) are coordinated, evidence-based interventions designed to optimize antibiotic prescribing — ensuring patients receive the right antibiotic, at the right dose, via the right route, for the right duration. The Public Health Agency of Canada and Health Canada jointly support national ASP frameworks implemented across Canadian hospitals and community settings.
Core Principles of Canadian Antimicrobial Stewardship
-
1
Appropriate Indication: Antibiotics should only be prescribed when a bacterial infection is clinically confirmed or highly probable. Viral upper respiratory infections, uncomplicated bronchitis in otherwise healthy adults, and many cases of sinusitis do not warrant antibiotic therapy.
-
2
Agent Selection: The narrowest-spectrum agent effective against the suspected or confirmed pathogen should be preferred. Broad-spectrum agents should be reserved for confirmed resistant organisms or empiric coverage of high-risk patients.
-
3
Dose Optimization: Pharmacokinetic-pharmacodynamic (PK/PD) principles should guide dosing. Time-dependent killing antibiotics (beta-lactams) require sufficient time above MIC; concentration-dependent antibiotics (aminoglycosides, fluoroquinolones) require peak concentration optimization.
-
4
Duration of Therapy: Shorter antibiotic courses (5–7 days for many common infections) achieve equivalent clinical cure rates compared to traditional longer courses (10–14 days) while reducing selective pressure for resistance and adverse effects including Clostridioides difficile infection.
-
5
IV-to-Oral Conversion: Early transition from intravenous to oral antibiotics in appropriate patients reduces hospital length of stay, IV-related complications, and healthcare costs without compromising outcomes for many infection types.
6. Canadian Antibiotic Prescribing Standards
The Canadian Medical Association (CMA), the College of Family Physicians of Canada (CFPC), and the Association of Medical Microbiology and Infectious Disease Canada (AMMI Canada) collaboratively develop clinical practice guidelines for antibiotic prescribing in community and hospital settings. These guidelines are informed by Canadian epidemiological resistance surveillance data from the Canadian Antimicrobial Resistance Alliance (CARA) and the Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS).
Notable differences between Canadian and US prescribing practice include a generally more conservative approach to fluoroquinolone prescribing in Canada, reflecting earlier provincial formulary restrictions in response to resistance emergence. Canadian provincial drug benefit formularies also influence prescribing patterns, with first-line agents for common infections often specified in provincial clinical practice guidelines.
In Canada, all antibiotic agents except topical formulations for minor skin conditions require a valid prescription issued by a licensed physician, nurse practitioner, or (in some provinces) a pharmacist operating under a prescribing authority. No Canadian pharmacy complying with Health Canada and provincial pharmacy college regulations will dispense systemic antibiotics without a valid prescription.
7. Health Canada Regulation of Antibiotic Agents
Antibiotic drugs in Canada are regulated under the Food and Drugs Act and its associated Regulations. New antibiotic submissions are evaluated by Health Canada's Biologic and Radiopharmaceutical Drugs Directorate (BRDD) or the Therapeutic Products Directorate (TPD) depending on the nature of the agent. The evaluation criteria include:
- Quality (pharmaceutical chemistry, manufacturing, stability)
- Safety (preclinical toxicology, clinical adverse effects)
- Efficacy (clinical trial evidence for the proposed indications)
- Antimicrobial resistance risk assessment
Health Canada's Guidance for Industry: Conduct and Analysis of Comparative Bioavailability Studies governs generic antibiotic approvals through the ANDS pathway, applying the same 80–125% bioequivalence confidence interval standard as the FDA. All marketed antibiotics are assigned a Drug Identification Number (DIN) searchable in the Health Canada Drug Product Database.
Post-market surveillance of antibiotic safety signals is conducted through the Canada Vigilance Program, with serious adverse drug reactions (ADRs) reportable by healthcare professionals and consumers. Health Canada has the authority to issue safety advisories, require labeling updates, or withdraw marketing authorizations based on post-market safety data — a framework parallel to the FDA's MedWatch system.
Key References
- 1. Public Health Agency of Canada. Pan-Canadian Action Plan on Antimicrobial Resistance and Use. 2023.
- 2. AMMI Canada/CACMID. Canadian Guidelines for Antimicrobial Stewardship in Hospitals. 2021.
- 3. Health Canada Drug Product Database. health-products.canada.ca.
- 4. WHO. Global Antimicrobial Resistance and Use Surveillance System (GLASS). 2023 Report.
- 5. Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS). Annual Reports.
- 6. Eliopoulos GM, Roberts MC. Antibiotic Resistance: Mechanisms. In: Mandell, Douglas & Bennett's Principles of Infectious Diseases. 9th ed. 2019.